dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Kilpeläinen, Athina |
dc.contributor.author | Saubí Roca, Narcís |
dc.contributor.author | Guitart, Núria |
dc.contributor.author | Olvera, Alex |
dc.contributor.author | Hanke, Tomáš |
dc.contributor.author | Brander, Christian |
dc.contributor.author | Joseph Munné, Joan |
dc.date.accessioned | 2020-02-24T10:59:21Z |
dc.date.available | 2020-02-24T10:59:21Z |
dc.date.issued | 2019-08-02 |
dc.identifier.citation | Kilpeläinen A, Saubi N, Guitart N, Olvera A, Hanke T, Brander C, et al. Recombinant BCG expressing HTI prime and recombinant ChAdOx1 boost is safe and elicits HIV-1-specific T-cell responses in BALB/c mice. Vaccines. 2019 Aug 2;7(3):78. |
dc.identifier.issn | 2076-393X |
dc.identifier.uri | https://hdl.handle.net/11351/4671 |
dc.description | BCG; VIH; Vacuna |
dc.description.sponsorship | This research was funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 681137 and supported by Instituto de Salud Carlos III FIS PI14/00494. EAVI2020. In addition, it has been supported by the ISCIII, RETIC-RIS RD12/0017, and the HIVACAT Research Program. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Vaccines;7(3) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mycobacterium tuberculosis |
dc.subject | Vacunes antivíriques |
dc.subject | Sida - Vacunació |
dc.subject.mesh | AIDS Vaccines |
dc.subject.mesh | Immunogenicity, Vaccine |
dc.subject.mesh | Mycobacterium bovis |
dc.title | Recombinant BCG expressing HTI prime and recombinant ChAdOx1 boost is safe and elicits HIV-1-specific T-cell responses in BALB/c mice |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/vaccines7030078 |
dc.subject.decs | vacunas para SIDA |
dc.subject.decs | inmunogenicidad vacunal |
dc.subject.decs | Mycobacterium bovis |
dc.relation.publishversion | https://www.mdpi.com/2076-393X/7/3/78 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Kilpeläinen A, Saubi N, Joseph J] Catalan Center for HIV Vaccine Research and Development, AIDS Research Unit, Servei de Malalties Infeccioses, Hospital Clínic/Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Hospital Universitari Vall d’Hebron, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Guitart N] Catalan Center for HIV Vaccine Research and Development, AIDS Research Unit, Servei de Malalties Infeccioses, Hospital Clínic/Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. [Olvera A] Irsicaixa AIDS Research Institute, Badalona, Spain. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain. [Hanke T] Nueld Department of Medicine, The Jenner Institute, University of Oxford, Oxford, UK. International Research Center of Medical Sciences (IRCMS), Kumamoto University, Kumamoto, Japan. [Brander C] ] Irsicaixa AIDS Research Institute, Badalona, Spain. Universitat de Vic-Universitat Central de Catalunya (UVic-UCC), Barcelona, Spain. ICREA, Barcelona, Spain. AELIX Therapeutics, Barcelona, Spain |
dc.identifier.pmid | 31382453 |
dc.identifier.wos | 000487982000034 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |